Joydeep Nag

Mr. Joydeep Nag

Rajiv Gandhi Centre for Biotechnology
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
UKUmerali Kunnakkadan
Umerali Kunnakkadan
JNJoydeep Nag
Joydeep Nag
NKNisha Asok Kumar
Nisha Asok Kumar
RMReshma Koolaparambil Mukesh
Reshma Koolaparambil Mukesh
SSSreenath Muraleedharan Suma
Sreenath Muraleedharan Suma
JJJohn Johnson
John Johnson
Among the innate immune sentinels, the complement system is a formidable first line of defense against pathogens, including viruses. Chandipura virus (CHPV), a neurotropic vesiculovirus of the family Rhabdoviridae, is a deadly human pathogen known to cause fatal encephalitis, especially among children. The nature of interaction and the effect of human complement on CHPV are unknown. Here, we report that CHPV is a potent activator of complement and, thus, is highly sensitive to complement proteins in normal human serum (NHS). Utilizing a panel of specific complement component depleted/reconstituted human serum, we have demonstrated that CHPV neutralization is C3, C4, and C1q dependent and independent of factor B, suggesting the importance of the classical pathway in limiting CHPV. Employing a range of biochemical approaches, we showed (i) a direct association of C1q to CHPV, (ii) deposition of complement proteins C3b, C4b, and C1q on CHPV, and (iii) virus aggregation. Depletion of C8, an important component of the pore-forming complex of complement, had no effect on CHPV, further supporting the finding that aggregation and not virolysis is the mechanism of virus neutralization. With no approved vaccines or treatment modalities in place against CHPV, insights into such interactions can be exploited to develop potent vaccines or therapeutics targeting CHPV. IMPORTANCE Chandipura virus is a clinically important human pathogen of the Indian subcontinent. The rapidity of death associated with CHPV infection in addition to the absence of an effective vaccine or therapeutics results in poor clinical prognosis. The biology of the virus and its interaction with the host immune system, including the complement system, are understudied. Our investigation reveals the susceptibility of CHPV to fluid phase complement and also dissects the pathway involved and the mechanism of virus neutralization. Direct binding of C1q, an important upstream component of the classical pathway of complement to CHPV, and the strong dependency on C1q for virus neutralization highlight the significance of identifying such interactions to better understand CHPV pathogenesis and devise strategies to target this deadly pathogen.

17 March 2020 in Journal of Virology
Verified
Journal Article
Closed access
JNJoydeep Nag
Joydeep Nag
RMReshma Koolaparambil Mukesh
Reshma Koolaparambil Mukesh
SSSreenath Muraleedharan Suma
Sreenath Muraleedharan Suma
UKUmerali Kunnakkadan
Umerali Kunnakkadan
NKNisha Asok Kumar
Nisha Asok Kumar
JJJohn Johnson
John Johnson
Chikungunya virus is a vector-borne pathogen of global significance. The morbidity associated with chikungunya virus (CHIKV) infection, neurovirulence and adaptability toAedes albopictus, necessitates a deeper understanding of the interaction of CHIKV with the host immune system. Here, we demonstrate that CHIKV is resistant to neutralization by one of the potent barriers of the innate immune arm, the complement system. Chikungunya virus showed marked resistance to complement despite activation and deposition of complement proteins. Interestingly the C3 component associated with the virion was found to be inactive C3b (iC3b), a key factor implicated in the pathogenesis and disease severity in the mouse model of Ross River virus infection. CHIKV also had an associated unique factor I-like activity that mediated the inactivation of C3b into iC3b. We have unraveled a smart strategy adopted by CHIKV to limit complement which has serious implications in viral dissemination, pathogenesis, and disease.

13 January 2023 in Current Clinical Microbiology Reports
Verified
Journal Article
Closed access
PDF file
JNJoydeep Nag
Joydeep Nag
JPJanvi Patel
Janvi Patel
Shashank TripathiShashank Tripathi
Shashank Tripathi

26 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NKNisha Asok Kumar
Nisha Asok Kumar
SSSreenath Muraleedharan Suma
Sreenath Muraleedharan Suma
UKUmerali Kunnakkadan
Umerali Kunnakkadan
JNJoydeep Nag
Joydeep Nag
RMReshma Mukesh
Reshma Mukesh
JJJohn Johnson
John Johnson
The human complement system is an important part of the innate immune system. Its effector pathways largely mediate virus neutralization. Vesicular stomatitis virus (VSV) activates the classical pathway of the complement, leading to virus neutralization by lysis. Two host-derived membrane-associated regulators of complement activation (RCA), CD55 and CD46, which are incorporated into the VSV envelope during egress, confer protection by delaying/resisting complement-mediated neutralization. We showed previously that CD55 is more effective than CD46 in the inhibition of neutralization. In this study, we identified that, at the protein level, VSV infection resulted in the down-regulation of CD46 but not CD55. The mRNA of both the RCAs was significantly down-regulated by VSV, but it was delayed in the case of CD55. The immunoblot analysis of the levels of RCAs in the progeny virion harvested at three specific time intervals, points to an equal ratio of its distribution relative to viral proteins. Besides reconfirming the dominant role of CD55 over CD46 in shielding VSV from complement, our results also highlight the importance of the subtle modulation in the expression pattern of RCAs in a system naturally expressing them.

11 September 2018 in Molecular Immunology
Verified
Journal Article
Closed access
JNJoydeep Nag
Joydeep Nag
JJJohn Bernet Johnson
John Bernet Johnson